ECOG-1594

Regimen

Experimental
cisplatin+paclitaxel vs cisplatin+gemcitabine vs cisplatin+docetaxel
Control
cisplatin+paclitaxel (reference)

Population

Stage IIIB/IV advanced NSCLC, chemo-naive

Key finding

No platinum doublet superior to another; mOS ~7.9 mo, 1-yr OS 33%; established 'no best regimen' plateau for unselected NSCLC

Source: PMID 11784875

Timeline

    Guideline citations

    • CSCO NSCLC 2025 ⚠️ OCR source